EVOK Evoke Pharma
- 0.4770
- +0.0071+1.51%
Evoke Pharma News
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
Evoke Pharma Reiterates FY24 Net Revenue ~$14M Vs $14.081 Est.
Evoke Pharma Reiterates FY24 Net Revenue ~$14M Vs $14.081 Est.
Evoke Pharma Q1 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate, Sales $1.74M Miss $2.14M Estimate
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. The company reported quarterly sales of $1.74 million
Evoke Pharma Backs FY24 Rev $14M >EVOK
Evoke Pharma Backs FY24 Rev $14M >EVOK
Evoke Pharma | 10-Q: Quarterly report
Evoke Pharma 1Q Loss/Shr 17c >EVOK
Evoke Pharma 1Q Loss/Shr 17c >EVOK
Press Release: Evoke Pharma Reports First Quarter 2024 Financial Results
Evoke Pharma Reports First Quarter 2024 Financial Results 114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms comp
Evoke Pharma | 10-K/A: Annual report (Amendment)
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Evoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer
By Denny Jacob Evoke Pharma tapped Matthew D'Onofrio to succeed David Gonyer as chief executive, effective March 31. D'Onofrio, who currently serves as president and chief operating officer, will as
Evoke Pharma : Matthew D'Onofrio Will Be Succeeding David Gonyer as CEO as of March 31 >EVOK
Evoke Pharma : Matthew D'Onofrio Will Be Succeeding David Gonyer as CEO as of March 31 >EVOK
Evoke Pharma: Gonyer's Departure Is for Personal Reasons >EVOK
Evoke Pharma: Gonyer's Departure Is for Personal Reasons >EVOK
Press Release: Evoke Pharma Announces Senior Leadership Transition With Promotion of Matthew J. D'Onofrio to Chief Executive Officer
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASD
Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript
Earnings Call Summary | Evoke Pharma(EVOK.US) Q4 2023 Earnings Conference
The following is a summary of the Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript:Financial Performance:Evoke Pharma reported net revenue for GIMOTI doubled over the last year.New prescript
Evoke Pharma Sees FY24 Net Revenue ~$14M Vs $14.017M Est.
Evoke Pharma Sees FY24 Net Revenue ~$14M Vs $14.017M Est.
Recap: Evoke Pharma Q4 Earnings
Evoke Pharma (NASDAQ:EVOK) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:10 PM.Here's what investors need to know about the announcement.EarningsEvoke Pharma missed estimated earn
Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50) by 18 percent. The company reported quarterly sales of $1.676 million
Analysis
Price Target
No Data
